v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Apr. 24, 2026
Apr. 25, 2025
Apr. 26, 2024
Operating Activities:      
Net income $ 4,837 $ 4,691 $ 3,705
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 2,958 2,861 2,647
Provision for credit losses 136 123 90
Deferred income taxes 51 (316) (508)
Stock-based compensation 457 429 393
Asset impairments and related inventory write-downs 0 0 371
Other, net 314 310 573
Change in operating assets and liabilities, net of acquisitions and divestitures:      
Accounts receivable, net (200) (433) (391)
Inventories (404) (292) (139)
Accounts payable and accrued liabilities 46 209 391
Other operating assets and liabilities (865) (538) (345)
Net cash provided by operating activities 7,330 7,044 6,787
Investing Activities:      
Acquisitions, net of cash acquired (406) (98) (211)
Additions to property, plant, and equipment (1,904) (1,859) (1,587)
Purchases of investments (8,725) (8,226) (7,748)
Sales and maturities of investments 8,105 8,495 7,441
Other investing activities, net (4) (249) (261)
Net cash used in investing activities (2,934) (1,937) (2,366)
Financing Activities:      
Change in current debt obligations, net 9 (1,070) 1,073
Issuance of long-term debt 1,747 3,209 0
Payments on long-term debt (2,930) 0 0
Dividends to shareholders (3,639) (3,589) (3,666)
Issuance of ordinary shares 516 508 284
Repurchase of ordinary shares (1,035) (3,235) (2,138)
Proceeds from MiniMed initial public offering 538 0 0
Other financing activities, net 44 (184) (3)
Net cash used in financing activities (4,751) (4,361) (4,450)
Effect of exchange rate changes on cash and cash equivalents 85 188 (230)
Net change in cash and cash equivalents (269) 934 (259)
Cash and cash equivalents at beginning of period 2,218 1,284 1,543
Cash and cash equivalents at end of period 1,949 2,218 1,284
Cash paid for:      
Income taxes 1,942 1,819 1,622
Interest $ 774 $ 762 $ 826